Novo Nordisk has come to the defense of its new obesity drug, CagriSema, after data from late-stage trials caused concern among investors, resulting in a $125 billion hit to its market value. Company executives insist the drug shows superior weight-loss results compared to their popular Wegovy treatment.
About the Author
